2020 Emerging Topic Conference: Intrahepatic Cholangiocarcinoma: The Next Horizon
Image For Activity Cover
3 Courses
Credit Offered
No Credit Offered
  • Overview
  • Learning Objectives
  • Target Audience
  • Faculty and Disclosures
  • Recommended
This Emerging Topic Conference focuses on the basic, translational and clinical aspects of intrahepatic cholangiocarcinoma (iCCA). Emerging molecular technologies provide platforms to better unravel the molecular pathogenesis of iCCA, and the role of the tumor immune microenvironment. This conference will review these advances in pathogenesis iCCA, its clinical management and future challenges, with an emphasis on addressing unmet clinical needs.

Upon completion of this activity, learners will be able to:

  • Formulate a state-of-the-art review of recent research and treatment advances in iCCA, with particular emphasis on present and future and treatment opportunities.
  • Define and reconcile current areas of controversy.
  • Delineate future avenues of research and highlight translational opportunities for novel therapies in iCCA.

This activity was planned in the context of the following ACGME/IOM/IPEC competencies: Evidence-based Practice, Medical Knowledge, Interpersonal and Communication Skills, Roles/Responsibilities and Work in Interdisciplinary Teams 

  • Hepatologists
  • Gastroenterologists
  • Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Transplant Coordinators
  • Surgeons
  • Fellows/Trainees
  • Medical Oncologists
AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

The organizers and faculty have reported the following disclosures:

Jesus Banales, PhD
Nothing to disclose.

Nabeel M. Bardeesy, PhD
Nothing to disclose.

Mitesh Borad, MD
Nothing to disclose.

Umberto Cillo, MD
Nothing to disclose.

Laura Dawson, MD, FRCPC
Nothing to disclose.

Luca Fabris, MD, PhD
Nothing to disclose.

Gregory  J. Gores, MD, FAASLD
Scientific Consulting: Co-editor of Seminars in Liver Disease

Tim Greten, MD
Nothing to disclose.

Julie Heimbach, MD, FAASLD
Advisory Committees and/or Review Panels: ASTS Council

Kimberly JoHong, MD
Nothing to disclose.

Jill Koshiol, PhD
Nothing to disclose.

Stacie Lindsey
Nothing to disclose.

Jospe M. Llovet, MD, FAASLD
Scientific Consulting: Can-Fite Biopharma, Eli Lilly, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Eisai Inc, Celsion Corporation, Exelixis, Merck, Ipsen, Genentech, Roche, Glycotest, Leerink Swann LLC, Fortress Biotech, Nucleix, Sirtex, Mina Alpha Ltd, AstraZeneca
Grants/Research Support: Bayer HealthCare Pharmaceuticals, Eisai Inc, Bristol-Myers Squibb, Boehringer-Ingelheim and Ipsen

David C. Madoff, MD
Nothing to disclose.

Shishri K. Maithel, MD
Grants/Research Support: Celgene

Valerie Paradis,  MD, PhD
Nothing to disclose.

Tushar Patel, MBCbB, FAASLD
Nothing to disclose.

Sumera H. Rizvi, MD
Nothing to disclose.

Florin M. Selaru, MD
Nothing to disclose.

Daniela Sia, PhD
Nothing to disclose.

Mario Strazzabosco, MD, PhD, FAASLD
Scientific Consulting: Bayer, Engitix

Andrew X. Zhu, MD, PhD
Scientific Consulting: Bayer, Merck, Lilly, Novartis, Eisai, Roche-Genentech, Exelixis

Basic Research Committee
Muyiwa Awoniyi, MD, PhD
Nothing to disclose

Lily Dara, MD
Nothing to disclose

Laurie D. DeLeve, MD, PhD, FAASLD
Intellectual Property Rights (Patents, Royalties, Licensing fees): COMPOSITIONS AND METHODS FOR AMELIORATING TISSUE INJURY, ENHANCING LIVER REGENERATION AND STEM CELL THERAPIES, 2017-230-01 US no. 62/544,589 End-organ selective MMP inhibition enhances bone marrow progenitor cell recruitment (sole inventor) Applicant: University of Southern California GBC ref.: 6177.132445PCT
Scientific Consultant/Advisor to Industry or Commercial Enterprise: Abbvie; Daiichi Sankyo

Ariel E. Feldstein, MD
Scientific Consultant/Advisor to Industry or Commercial Enterprise: Gilead, Merck, Oppilan Pharma, GSK

Sandy Feng, MD, PhD
Stock/Stock Options: Amgen, Johnson & Johnson, Stryker, Abbott, Charles River Labs, Eli Lily, Express Scripts, Glaxo-Smith Klein, Medco, Merck, Pfizer, Hospira
Grants/Research Support: Novartis, Quark
Leadership in related society: Juno Therapeutics, Inc., American Journal of Transplantation, Immune Tolderance Network, OPTN/UNOS, The New England Journal of Medicine

Mercedes Fernandez, PhD
Nothing to disclose

Rohit Kohli, MBBS, MS, FAASLD
Commercial Speaker's Bureau: Alexion Pharmaceuticals
Data Safety Monitoring Board for Industry or Commercial Enterprise: Takeda Pharmacrutical
Grants/Research Support: Epigen Pharma, Vision Pharmaceuticals
Leadership in related society: NASPGHAN Foundation Board

T. Jake Liang, MD, FAASLD
Nothing to disclose

Pranoti Mandrekar, PhD, FAASLD
Nothing to disclose

Kaitlyn R. Musto, PA-C
Nothing to disclose

Laura E. Nagy, PhD, FAASLD
Nothing to disclose

Kari Nejak-Bowen, MBA, PhD
Nothing to disclose

Ruisi Wang, PhD
Nothing to disclose

Huiping Zhou, PhD, FAASLD
Nothing to disclose

Clinical Research Committee
Ulrich Beuers, MD
Scientific Consultant/Advisor to Industry or Commercial Enterprise, including Development of Educational Presentations: Valeant, Norgine
Grants/Research Support: Valeant, Grifols
Leadership in related society: ACG: American Journal of Gastroenterology AE, AGA: Microbiome Scientific Advisory Board;

Jasmohan S. Bajaj, MD, FAASLD
Grants/Research Support: Lallemand Pharma; Commercial Speaker's Bureau: Lupin Pharma

Mamatha Bhat, MD
Nothing to disclose

Therese Bittermann, MD
Nothing to disclose

Edward Doo, MD
Grants/Research Support: Abbvie, BMS, Gilead
Scientific Consultant/Advisor to Industry or Commercial Enterprise: Abbvie, Gilead

W. Ray Kim, MD, FAASLD
Advisory Board: Merck, Gilead Science, Abbvie, Salix
Scientific Consultant/Advisor to Industry or Commercial Enterprise: Connatus

Paul Yien Kwo, MD, FAASLD
Grants/Research Support: Allergan, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Galectin Therapeutics, Galmed Pharmaceuticals, GE, Genfit, Gilead, Intercept, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Pfizer, and Siemens
Scientific Consultant/Advisor to Industry or Commercial Enterprise: Glympse bio, Metacrine, Viking, Ini Pharma Ionis, Intercept, Ionis, Janssen Inc., Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer,Madrigagal

Rohit Loomba, MD
Nothing to disclose

Arpan Arun Patel, MD
Grants/Research Support: Gilead, Shire

Emily J. Rothbaum Perito, MD
Nothing to disclose

Susan M. Salahshor, PhD, PA-C
Grants/Research Support: Organ Recovery Systems

Shimul A. Shah, MD
Nothing to disclose

Tracey G. Simon, MD
Nothing to disclose

James E. Squires, MD, MS
Nothing to disclose

Monica A. Tincopa, MD MSc
Nothing to disclose

Kymberly Watt, MD
Expert Testimony: Intercept - site- PI Gilead - site PI, co-I Conatus - site co-I Novartis - previous site PI, co author study subanalysis Pfizer- site co-I all multicenter study related
Stock/Stock Options: BMS; Arbutus; Madrigal; Viking

AASLD Staff 
Dominique Clayton
Nothing to disclose

Julie Deal
Nothing to disclose 

Matthew D’Uva
Nothing to disclose

Denise Seise
Nothing to disclose

Suzanne Thibeault
Nothing to disclose

Anne Wrobel
Nothing to disclose
Powered By